Wall Street analysts forecast that Assembly Biosciences Inc (NASDAQ:ASMB) will post earnings per share of ($0.55) for the current quarter, Zacks reports. Four analysts have made estimates for Assembly Biosciences’ earnings, with the highest EPS estimate coming in at $0.17 and the lowest estimate coming in at ($0.84). Assembly Biosciences posted earnings of ($0.72) per share during the same quarter last year, which suggests a positive year over year growth rate of 23.6%. The firm is scheduled to report its next earnings report on Monday, August 3rd.
According to Zacks, analysts expect that Assembly Biosciences will report full year earnings of ($3.13) per share for the current year, with EPS estimates ranging from ($3.58) to ($2.32). For the next fiscal year, analysts forecast that the firm will post earnings of ($4.03) per share, with EPS estimates ranging from ($5.76) to ($3.22). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.98) by $0.22. Assembly Biosciences had a negative return on equity of 45.43% and a negative net margin of 601.75%. The business had revenue of $4.08 million during the quarter, compared to the consensus estimate of $3.82 million.
Shares of NASDAQ ASMB traded up $0.65 during trading on Friday, reaching $23.81. The stock had a trading volume of 166,900 shares, compared to its average volume of 261,602. Assembly Biosciences has a one year low of $8.13 and a one year high of $25.07. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.14 and a current ratio of 12.14. The stock has a market cap of $757.85 million, a PE ratio of -6.94 and a beta of 1.26. The firm’s 50 day moving average price is $20.86 and its two-hundred day moving average price is $18.82.
In other news, EVP Richard James Colonno sold 7,812 shares of the company’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $15.04, for a total value of $117,492.48. Following the completion of the sale, the executive vice president now owns 144,821 shares in the company, valued at $2,178,107.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 12.42% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Bank of Montreal Can raised its holdings in Assembly Biosciences by 34.8% in the 4th quarter. Bank of Montreal Can now owns 3,440 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 889 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in Assembly Biosciences by 188.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 8,620 shares of the biopharmaceutical company’s stock valued at $128,000 after acquiring an additional 5,633 shares in the last quarter. Citigroup Inc. raised its holdings in Assembly Biosciences by 130.0% in the 4th quarter. Citigroup Inc. now owns 6,761 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 3,822 shares in the last quarter. Aperio Group LLC acquired a new position in Assembly Biosciences in the 1st quarter valued at approximately $149,000. Finally, Commonwealth Equity Services LLC acquired a new position in Assembly Biosciences in the 1st quarter valued at approximately $152,000. 88.34% of the stock is owned by hedge funds and other institutional investors.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
See Also: Institutional Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.